American Journal of Kidney Diseases
Volume 52, Issue 2 , Pages 353-365 , August 2008

Fatigue in Patients Receiving Maintenance Dialysis: A Review of Definitions, Measures, and Contributing Factors

  • Manisha Jhamb, MD, MPH

      Affiliations

    • Western Pennsylvania Medical Center, Pittsburgh, PA
    • ,
  • Steven D. Weisbord, MD, MSc

      Affiliations

    • Renal Section and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA
    • Renal-Electrolyte Division, University of Pittsburgh Medical Center, Pittsburgh, PA
    • ,
  • Jennifer L. Steel, PhD

      Affiliations

    • University of Pittsburgh School of Medicine, Liver Cancer Center, Department of Surgery, Starzl Transplantation Institute, Pittsburgh, PA
    • ,
  • Mark Unruh, MD, MSc

      Affiliations

    • Renal-Electrolyte Division, University of Pittsburgh Medical Center, Pittsburgh, PA.
    • Corresponding Author InformationAddress correspondence to Mark Unruh, MD, MSc, University of Pittsburgh Medical Center, Renal-Electrolyte Division, 3550 Terrace St, A915 Scaife Hall, Pittsburgh, PA 15261.

Received 3 December 2007 ,Accepted 7 May 2008.

References 

  1. Cardenas DD, Kutner NG. The problem of fatigue in dialysis patients. Nephron. 1982;30:336–340
  2. Chang WK, Hung KY, Huang JW, Wu KD, Tsai TJ. Chronic fatigue in long-term peritoneal dialysis patients. Am J Nephrol. 2001;21:479–485
  3. Laupacis A, Muirhead N, Keown P, Wong C. A disease-specific questionnaire for assessing quality of life in patients on hemodialysis. Nephron. 1992;60:302–306
  4. Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: A systematic review. Adv Chronic Kidney Dis. 2007;14:82–99
  5. Parfrey PS, Vavasour HM, Henry S, Bullock M, Gault MH. Clinical features and severity of nonspecific symptoms in dialysis patients. Nephron. 1988;50:121–128
  6. Unruh M, Benz R, Greene T, et al. Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney Int. 2004;66:355–366
  7. Weisbord SD, Fried LF, Arnold RM, et al. Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients. J Am Soc Nephrol. 2005;16:2487–2494
  8. Ramkumar N, Beddhu S, Eggers P, Pappas LM, Cheung AK. Patient preferences for in-center intense hemodialysis. Hemodial Int. 2005;9:281–295
  9. Weisbord SD, Fried LF, Mor MK, et al. Renal provider recognition of symptoms in patients on maintenance hemodialysis. Clin J Am Soc Nephrol. 2007;2:960–967
  10. Lindsay RM, Heidenheim PA, Nesrallah G, Garg AX, Suri R. Minutes to recovery after a hemodialysis session: A simple health-related quality of life question that is reliable, valid, and sensitive to change. Clin J Am Soc Nephrol. 2006;1:952–959
  11. Stone P, Richards M, Hardy J. Fatigue in patients with cancer. Eur J Cancer. 1998;34:1670–1676
  12. Lee KA, Hicks G, Nino-Murcia G. Validity and reliability of a scale to assess fatigue. Psychiatry Res. 1991;36:291–298
  13. Lai JS, Chen WH. Fatigue Archival Analysis Report. www.nihpromis.orgAccessed March 3, 2008
  14. Ream E, Richardson A. Fatigue: A concept analysis. Int J Nurs Stud. 1996;33:519–529
  15. Lenz ER, Pugh LC, Milligan RA, Gift A, Suppe F. The middle-range theory of unpleasant symptoms: An update. ANS Adv Nurs Sci. 1997;19:14–27
  16. Chaudhuri A, Behan PO. Fatigue and basal ganglia. J Neurol Sci. 2000;179(suppl 1-2):S34–S42
  17. Lee BO, Lin CC, Chaboyer W, Chiang CL, Hung CC. The fatigue experience of haemodialysis patients in Taiwan. J Clin Nurs. 2007;16:407–413
  18. Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W. Progress toward guidelines for the management of fatigue. Oncology (Williston Park). 1998;12:369–377
  19. Kalantar-Zadeh K, Unruh M. Health related quality of life in patients with chronic kidney disease. Int Urol Nephrol. 2005;37:367–378
  20. Unruh ML, Weisbord SD, Kimmel PL. Health-related quality of life in nephrology research and clinical practice. Semin Dial. 2005;18:82–90
  21. Davison SN, Jhangri GS, Johnson JA. Cross-sectional validity of a modified Edmonton symptom assessment system in dialysis patients: A simple assessment of symptom burden. Kidney Int. 2006;69:1621–1625
  22. Dagnelie PC, Pijls-Johannesma MC, Pijpe A, et al. Psychometric properties of the revised Piper Fatigue Scale in Dutch cancer patients were satisfactory. J Clin Epidemiol. 2006;59:642–649
  23. Piper BF, Dibble SL, Dodd MJ, Weiss MC, Slaughter RE, Paul SM. The revised Piper Fatigue Scale: Psychometric evaluation in women with breast cancer. Oncol Nurs Forum. 1998;25:677–684
  24. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39:315–325
  25. McCann K, Boore JR. Fatigue in persons with renal failure who require maintenance haemodialysis. J Adv Nurs. 2000;32:1132–1142
  26. Chandran V, Bhella S, Schentag C, Gladman DD. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis. 2007;66:936–939
  27. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367:29–35
  28. Wadler S, Brain C, Catalano P, Einzig AI, Cella D, Benson AB. Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: Eastern Cooperative Oncology Group Study E6296. Cancer J. 2002;8:282–286
  29. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13:63–74
  30. Curran SL, Beacham AO, Andrykowski MA. Ecological momentary assessment of fatigue following breast cancer treatment. J Behav Med. 2004;27:425–444
  31. Hacker ED, Ferrans CE. Ecological momentary assessment of fatigue in patients receiving intensive cancer therapy. J Pain Symptom Manage. 2007;33:267–275
  32. Moskowitz DS, Young SN. Ecological momentary assessment: What it is and why it is a method of the future in clinical psychopharmacology. J Psychiatry Neurosci. 2006;31:13–20
  33. Pagels A, Heiwe S, Hylander B. Nutritional status of pre-dialysis patients. EDTNA ERCA J. 2006;32:162–166
  34. Brunier GM, Graydon J. The influence of physical activity on fatigue in patients with ESRD on hemodialysis. ANNA J. 1993;20:457–461discussion 62, 521
  35. Liu HE. Fatigue and associated factors in hemodialysis patients in Taiwan. Res Nurs Health. 2006;29:40–50
  36. Unruh M, Miskulin D, Yan G, et al. Racial differences in health-related quality of life among hemodialysis patients. Kidney Int. 2004;65:1482–1491
  37. Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun. 2007;21:153–160
  38. Ganz PA, Bower JE. Cancer related fatigue: A focus on breast cancer and Hodgkin's disease survivors. Acta Oncol. 2007;46:474–479
  39. Rao M, Wong C, Kanetsky P, et al. Cytokine gene polymorphism and progression of renal and cardiovascular diseases. Kidney Int. 2007;72:549–556
  40. Bergstrom J, Lindholm B, Lacson E, et al. What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients?. Semin Dial. 2000;13:163–175
  41. Herbelin A, Nguyen AT, Zingraff J, Urena P, Descamps-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int. 1990;37:116–125
  42. Memoli B, Minutolo R, Bisesti V, et al. Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes. Am J Kidney Dis. 2002;39:266–273
  43. Girndt M, Sester U, Kaul H, Kohler H. Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single-cell level. J Am Soc Nephrol. 1998;9:1689–1696
  44. Memoli B, Libetta C, Rampino T, et al. Hemodialysis related induction of interleukin-6 production by peripheral blood mononuclear cells. Kidney Int. 1992;42:320–326
  45. Le Meur Y, Lorgeot V, Aldigier JC, Wijdenes J, Leroux-Robert C, Praloran V. Whole blood production of monocytic cytokines (IL-1beta, IL-6, TNF-alpha, sIL-6R, IL-1Ra) in haemodialysed patients. Nephrol Dial Transplant. 1999;14:2420–2426
  46. Cesari M, Penninx BW, Pahor M, et al. Inflammatory markers and physical performance in older persons: The InCHIANTI Study. J Gerontol A Biol Sci Med Sci. 2004;59:242–248
  47. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106:506–512
  48. Janszky I, Lekander M, Blom M, Georgiades A, Ahnve S. Self-rated health and vital exhaustion, but not depression, is related to inflammation in women with coronary heart disease. Brain Behav Immun. 2005;19:555–563
  49. Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: The Health ABC Study. J Gerontol A Biol Sci Med Sci. 2002;57:M326–M332
  50. Kamimura MA, Draibe SA, Dalboni MA, et al. Serum and cellular interleukin-6 in haemodialysis patients: Relationship with energy expenditure. Nephrol Dial Transplant. 2007;22:839–844
  51. Wang AY, Sea MM, Tang N, et al. Resting energy expenditure and subsequent mortality risk in peritoneal dialysis patients. J Am Soc Nephrol. 2004;15:3134–3143
  52. Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE. The association between fatigue and inflammatory marker levels in cancer patients: A quantitative review. Brain Behav Immun. 2007;21:413–427
  53. Collado-Hidalgo A, Bower JE, Ganz PA, Cole SW, Irwin MR. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res. 2006;12:2759–2766
  54. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104:788–793
  55. Buchwald D, Wener MH, Pearlman T, Kith P. Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome. J Rheumatol. 1997;24:372–376
  56. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer. 2001;92(suppl 6):S1684–S1688
  57. Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol. 1995;13:575–582
  58. Balakrishnan VS, Guo D, Rao M, et al. Cytokine gene polymorphisms in hemodialysis patients: Association with comorbidity, functionality, and serum albumin. Kidney Int. 2004;65:1449–1460
  59. Kimmel PL, Phillips TM, Simmens SJ, et al. Immunologic function and survival in hemodialysis patients. Kidney Int. 1998;54:236–244
  60. Hopkins SJ. Central nervous system recognition of peripheral inflammation: A neural, hormonal collaboration. Acta Biomed. 2007;78(suppl 1):S231–S247
  61. Adams F, Quesada JR, Gutterman JU. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA. 1984;252:938–941
  62. Piepoli M, Clark AL, Volterrani M, Adamopoulos S, Sleight P, Coats AJ. Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure: Effects of physical training. Circulation. 1996;93:940–952
  63. Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 1998;32:107–114
  64. Brambilla F, Bellodi L, Perna G, Bertani A, Panerai A, Sacerdote P. Plasma interleukin-1 beta concentrations in panic disorder. Psychiatry Res. 1994;54:135–142
  65. Bremmer MA, Beekman AT, Deeg DJ, et al. Inflammatory markers in late-life depression: Results from a population-based study. J Affect Disord. 2008;106:249–255
  66. Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: A systematic review. J Am Coll Cardiol. 2005;45:1563–1569
  67. Trzonkowski P, Mysliwska J, Godlewska B, et al. Immune consequences of the spontaneous pro-inflammatory status in depressed elderly patients. Brain Behav Immun. 2004;18:135–148
  68. Yang JY, Huang JW, Chiang CK, et al. Higher plasma interleukin-18 levels associated with poor quality of sleep in peritoneal dialysis patients. Nephrol Dial Transplant. 2007;22:3606–3609
  69. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients (Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology). J Am Soc Nephrol. 2000;11:335–342
  70. Mann JF. What are the short-term and long-term consequences of anaemia in CRF patients?. Nephrol Dial Transplant. 1999;14(suppl 2):S29–S36
  71. Ross SD, Fahrbach K, Frame D, Scheye R, Connelly JE, Glaspy J. The effect of anemia treatment on selected health-related quality-of-life domains: A systematic review. Clin Ther. 2003;25:1786–1805
  72. Jones M, Ibels L, Schenkel B, Zagari M. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: A meta-analysis. Kidney Int. 2004;65:757–767
  73. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  74. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  75. Ossareh S, Roozbeh J, Krishnan M, Liakopoulos V, Bargman JM, Oreopoulos DG. Fatigue in chronic peritoneal dialysis patients. Int Urol Nephrol. 2003;35:535–541
  76. Chikotas N, Gunderman A, Oman T. Uremic syndrome and end-stage renal disease: Physical manifestations and beyond. J Am Acad Nurse Pract. 2006;18:195–202
  77. Pupim LB, Cuppari L, Ikizler TA. Nutrition and metabolism in kidney disease. Semin Nephrol. 2006;26:134–157
  78. Schreiber B. Levocarnitine and dialysis: A review. Nutr Clin Pract. 2005;20:218–243
  79. Brass EP, Adler S, Sietsema KE, Hiatt WR, Orlando AM, Amato A. Intravenous l-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. Am J Kidney Dis. 2001;37:1018–1028
  80. Wu AW, Fink NE, Marsh-Manzi JV, et al. Changes in quality of life during hemodialysis and peritoneal dialysis treatment: Generic and disease specific measures. J Am Soc Nephrol. 2004;15:743–753
  81. Cueto-Manzano AM, Gonzalez-Espinoza L, Martin del Campo F, Fortes PC, Pecoits-Filho R. Inflammation in peritoneal dialysis: A Latin-American perspective. Perit Dial Int. 2007;27:347–352
  82. Pecoits-Filho R, Stenvinkel P, Wang AY, Heimburger O, Lindholm B. Chronic inflammation in peritoneal dialysis: The search for the holy grail?. Perit Dial Int. 2004;24:327–339
  83. Yngman-Uhlin P, Edell-Gustafsson U. Self-reported subjective sleep quality and fatigue in patients with peritoneal dialysis treatment at home. Int J Nurs Pract. 2006;12:143–152
  84. Kutner NG. Quality of life and daily hemodialysis. Semin Dial. 2004;17:92–98
  85. Suri RS, Nesrallah GE, Mainra R, et al. Daily hemodialysis: A systematic review. Clin J Am Soc Nephrol. 2006;1:33–42
  86. Suri RS, Garg AX, Chertow GM, et al. Frequent Hemodialysis Network (FHN) randomized trials: Study design. Kidney Int. 2007;71:349–359
  87. Sklar A, Newman N, Scott R, Semenyuk L, Schultz J, Fiacco V. Identification of factors responsible for postdialysis fatigue. Am J Kidney Dis. 1999;34:464–470
  88. Sklar AH, Riesenberg LA, Silber AK, Ahmed W, Ali A. Postdialysis fatigue. Am J Kidney Dis. 1996;28:732–736
  89. Dreisbach AW, Hendrickson T, Beezhold D, Riesenberg LA, Sklar AH. Elevated levels of tumor necrosis factor alpha in postdialysis fatigue. Int J Artif Organs. 1998;21:83–86
  90. Lindsay RM, Kortas C. Hemeral (daily) hemodialysis. Adv Ren Replace Ther. 2001;8:236–249
  91. Heidenheim AP, Muirhead N, Moist L, Lindsay RM. Patient quality of life on quotidian hemodialysis. Am J Kidney Dis. 2003;42(suppl 1):S36–S41
  92. Kutner NG, Brogan D, Fielding B. Physical and psychosocial resource variables related to long-term survival in older dialysis patients. Geriatr Nephrol Urol. 1997;7:23–28
  93. Kutner NG, Lin LS, Fielding B, Brogan D, Hall WD. Continued survival of older hemodialysis patients: Investigation of psychosocial predictors. Am J Kidney Dis. 1994;24:42–49
  94. Aukrust P, Yndestad A, Smith C, Ueland T, Gullestad L, Damas JK. Chemokines in cardiovascular risk prediction. Thromb Haemost. 2007;97:748–754
  95. Merlino G, Piani A, Dolso P, et al. Sleep disorders in patients with end-stage renal disease undergoing dialysis therapy. Nephrol Dial Transplant. 2006;21:184–190
  96. Unruh ML, Levey AS, D'Ambrosio C, Fink NE, Powe NR, Meyer KB. Restless legs symptoms among incident dialysis patients: Association with lower quality of life and shorter survival. Am J Kidney Dis. 2004;43:900–909
  97. Unruh ML, Buysse DJ, Dew MA, et al. Sleep quality and its correlates in the first year of dialysis. Clin J Am Soc Nephrol. 2006;1:802–810
  98. Sanner BM, Tepel M, Esser M, et al. Sleep-related breathing disorders impair quality of life in haemodialysis recipients. Nephrol Dial Transplant. 2002;17:1260–1265
  99. Krueger JM, Fang J, Taishi P, Chen Z, Kushikata T, Gardi J. Sleep (A physiologic role for IL-1 beta and TNF-alpha). Ann N Y Acad Sci. 1998;856:148–159
  100. Mills PJ, Dimsdale JE. Sleep apnea: A model for studying cytokines, sleep, and sleep disruption. Brain Behav Immun. 2004;18:298–303
  101. Vgontzas AN, Zoumakis M, Bixler EO, et al. Impaired nighttime sleep in healthy old versus young adults is associated with elevated plasma interleukin-6 and cortisol levels: Physiologic and therapeutic implications. J Clin Endocrinol Metab. 2003;88:2087–2095
  102. Gul A, Aoun N, Trayner EM. Why do patients sleep on dialysis?. Semin Dial. 2006;19:152–157
  103. Entzian P, Linnemann K, Schlaak M, Zabel P. Obstructive sleep apnea syndrome and circadian rhythms of hormones and cytokines. Am J Respir Crit Care Med. 1996;153:1080–1086
  104. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: Role of sleep disturbance and obesity. J Clin Endocrinol Metab. 1997;82:1313–1316
  105. Hedayati SS, Bosworth HB, Kuchibhatla M, Kimmel PL, Szczech LA. The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients. Kidney Int. 2006;69:1662–1668
  106. Kimmel PL, Cukor D, Cohen SD, Peterson RA. Depression in end-stage renal disease patients: A critical review. Adv Chronic Kidney Dis. 2007;14:328–334
  107. Watnick S, Kirwin P, Mahnensmith R, Concato J. The prevalence and treatment of depression among patients starting dialysis. Am J Kidney Dis. 2003;41:105–110
  108. Bosker FJ, Westerink BH, Cremers TI, et al. Future antidepressants: What is in the pipeline and what is missing?. CNS Drugs. 2004;18:705–732
  109. Penninx BW, Kritchevsky SB, Yaffe K, et al. Inflammatory markers and depressed mood in older persons: Results from the Health, Aging and Body Composition Study. Biol Psychiatry. 2003;54:566–572
  110. Suarez EC, Lewis JG, Krishnan RR, Young KH. Enhanced expression of cytokines and chemokines by blood monocytes to in vitro lipopolysaccharide stimulation are associated with hostility and severity of depressive symptoms in healthy women. Psychoneuroendocrinology. 2004;29:1119–1128
  111. Lichtenstein GR, Bala M, Han C, DeWoody K, Schaible T. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis. 2002;8:237–243
  112. Lee SK, Lee HS, Lee TB, et al. The effects of antidepressant treatment on serum cytokines and nutritional status in hemodialysis patients. J Korean Med Sci. 2004;19:384–389
  113. Vgontzas AN, Bixler EO, Chrousos GP. Obesity-related sleepiness and fatigue: The role of the stress system and cytokines. Ann N Y Acad Sci. 2006;1083:329–344
  114. Nicklas BJ, Mychaleckyj J, Kritchevsky S, et al. Physical function and its response to exercise: Associations with cytokine gene variation in older adults with knee osteoarthritis. J Gerontol A Biol Sci Med Sci. 2005;60:1292–1298
  115. Wilund KR. Is the anti-inflammatory effect of regular exercise responsible for reduced cardiovascular disease?. Clin Sci (Lond). 2007;112:543–555
  116. Hung AM, Chertow GM, Young BS, Carey S, Johansen KL. Inflammatory markers are unrelated to physical activity, performance, and functioning in hemodialysis. J Ren Nutr. 2002;12:170–176
  117. Lee SW, Park GH, Lee SW, Song JH, Hong KC, Kim MJ. Insulin resistance and muscle wasting in non-diabetic end-stage renal disease patients. Nephrol Dial Transplant. 2007;22:2554–2562
  118. Rajan JY, Mitch JW. Muscle wasting in chronic kidney disease: The role of the ubiquitin proteasome system and its clinical impact. Pediatr Nephrol. 2008;23:527–535
  119. Fitts RH. Cellular mechanisms of muscle fatigue. Physiol Rev. 1994;74:49–94
  120. Johansen KL, Doyle J, Sakkas GK, Kent-Braun JA. Neural and metabolic mechanisms of excessive muscle fatigue in maintenance hemodialysis patients. Am J Physiol Regul Integr Comp Physiol. 2005;289:R805–R813
  121. Storer TW, Casaburi R, Sawelson S, Kopple JD. Endurance exercise training during haemodialysis improves strength, power, fatigability and physical performance in maintenance haemodialysis patients. Nephrol Dial Transplant. 2005;20:1429–1437
  122. Deligiannis A. Exercise rehabilitation and skeletal muscle benefits in hemodialysis patients. Clin Nephrol. 2004;61(suppl 1):S46–S50
  123. Tsay SL. Acupressure and fatigue in patients with end-stage renal disease—A randomized controlled trial. Int J Nurs Stud. 2004;41:99–106
  124. Tsay SL, Cho YC, Chen ML. Acupressure and transcutaneous electrical acupoint stimulation in improving fatigue, sleep quality and depression in hemodialysis patients. Am J Chin Med. 2004;32:407–416
  125. Yurtkuran M, Alp A, Yurtkuran M, Dilek K. A modified yoga-based exercise program in hemodialysis patients: A randomized controlled study. Complement Ther Med. 2007;15:164–171
  126. Mathiowetz VG, Finlayson ML, Matuska KM, Chen HY, Luo P. Randomized controlled trial of an energy conservation course for persons with multiple sclerosis. Mult Scler. 2005;11:592–601
  127. Feldt-Rasmussen B, Lange M, Sulowicz W, et al. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol. 2007;18:2161–2171
  128. Kotzmann H, Yilmaz N, Lercher P, et al. Differential effects of growth hormone therapy in malnourished hemodialysis patients. Kidney Int. 2001;60:1578–1585
  129. Minton O, Stone P, Richardson A, Sharpe M, Hotopf M. Drug therapy for the management of cancer related fatigue. Cochrane Database Syst Rev. 2008;1:CD006704
  130. Tong A, Lowe A, Sainsbury P, Craig JC. Experiences of parents who have children with chronic kidney disease: A systematic review of qualitative studies. Pediatrics. 2008;121:349–360

 Originally published online as doi:10.1053/j.ajkd.2008.05.005 on June 23, 2008.

PII: S0272-6386(08)00878-0

doi: 10.1053/j.ajkd.2008.05.005

American Journal of Kidney Diseases
Volume 52, Issue 2 , Pages 353-365 , August 2008

Article Tools

* Image Usage & Resolution